On October 23, 2012, I sent a detailed letter to the FDA which expressed my concerns about gadolinium toxicity caused by retained gadolinium from Gadolinium-based Contrast Agents (GBCAs). Because of the many recently published studies about gadolinium deposition in the brain and bones of patients with normal renal function, I decided that it was the right time to make my letter available to the public. While some progress has been made, four years have passed since I wrote that letter and I am concerned that the full scope of the problem still might not be addressed.
While I believe that the FDA took my concerns about gadolinium retention seriously, things are moving much too slowly. By making my letter public, I hope it will stimulate more interest in the issue of gadolinium retention and the plight of the many patients who have been adversely affected by its toxic effects.
You can download a copy of my 2012 Letter to the FDA in the Advocacy section. Please share it with your doctors and other affected patients.
To the medical professionals that follow us, I hope you will take time to read my entire letter. I am not a trained medical professional or scientist. However, I believe you will find my comments well-reasoned and fact-based.